The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

The U.S. Food and Drug Administration has granted approval to Empaveli as the primary treatment for C3 glomerulopathy .The drug has received approval for patients over 12 years and above who work to ...

The affected products were sold by retailers including Argos, B&M, DID, Lidl, Poundland, Robert Dyas, Tesco, and the Tower ...